RU2002129298A - APPLICATION OF GALANTAMINE FOR THE TREATMENT OF PSYCHONEUROLOGICAL BEHAVIOR ASSOCIATED WITH ALZHEIMER'S DISEASE - Google Patents
APPLICATION OF GALANTAMINE FOR THE TREATMENT OF PSYCHONEUROLOGICAL BEHAVIOR ASSOCIATED WITH ALZHEIMER'S DISEASE Download PDFInfo
- Publication number
- RU2002129298A RU2002129298A RU2002129298/14A RU2002129298A RU2002129298A RU 2002129298 A RU2002129298 A RU 2002129298A RU 2002129298/14 A RU2002129298/14 A RU 2002129298/14A RU 2002129298 A RU2002129298 A RU 2002129298A RU 2002129298 A RU2002129298 A RU 2002129298A
- Authority
- RU
- Russia
- Prior art keywords
- dose
- day
- galantamine
- administered
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (11)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19425900P | 2000-04-03 | 2000-04-03 | |
US60/194,259 | 2000-04-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2002129298A true RU2002129298A (en) | 2004-03-27 |
Family
ID=22716898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2002129298/14A RU2002129298A (en) | 2000-04-03 | 2001-03-28 | APPLICATION OF GALANTAMINE FOR THE TREATMENT OF PSYCHONEUROLOGICAL BEHAVIOR ASSOCIATED WITH ALZHEIMER'S DISEASE |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP1272192A2 (en) |
JP (1) | JP2003528913A (en) |
KR (1) | KR20020086911A (en) |
CN (1) | CN1430514A (en) |
AU (2) | AU2001265844B2 (en) |
BG (1) | BG107093A (en) |
BR (1) | BR0109770A (en) |
CA (1) | CA2310926C (en) |
CZ (1) | CZ20023543A3 (en) |
EE (1) | EE200200554A (en) |
HR (1) | HRP20020778A2 (en) |
HU (1) | HUP0300566A3 (en) |
IL (1) | IL152061A0 (en) |
MX (1) | MXPA02009777A (en) |
NO (1) | NO20024746L (en) |
PL (1) | PL361272A1 (en) |
RU (1) | RU2002129298A (en) |
SK (1) | SK15422002A3 (en) |
WO (1) | WO2001074339A2 (en) |
ZA (1) | ZA200207935B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6617361B2 (en) * | 1999-11-05 | 2003-09-09 | Be Able, Llc | Behavior chemotherapy |
RU2357734C2 (en) | 2003-07-25 | 2009-06-10 | Ф.Хоффманн-Ля Рош Аг | COMBINATION OF mGluR2 RECEPTOR ANTAGONIST AND AChE ENZYME INHIBITOR FOR ACUTE ANDN/OR CHRONIC NEURALGIC DISEASES |
DE10338544B4 (en) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccal formulations of galanthamine and their applications |
AU2009229372C1 (en) | 2008-03-27 | 2017-02-02 | Chase Pharmaceuticals Corporation | Use and composition for treating dementia |
WO2013160728A1 (en) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Dual targeting compounds for the treatment of alzheimer's disease |
BG66818B1 (en) * | 2013-03-07 | 2019-01-31 | Berbee Beheer B. V. | Composition of hippeastrum papilio extract for the production of medicines and nutritional supplements |
EP3297632A4 (en) * | 2015-05-18 | 2019-01-16 | Synaptec Development LLC | GALANTAMINE CLEARANCE OF AMYLOIDß |
CN117957003A (en) * | 2021-09-09 | 2024-04-30 | 上海日馨医药科技股份有限公司 | Methods of treating neurodegenerative diseases |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
DE19509663A1 (en) * | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Process for the isolation of galanthamine |
GB9600080D0 (en) * | 1996-01-04 | 1996-03-06 | Chiroscience Ltd | Resolution process |
JP5558648B2 (en) | 1998-11-23 | 2014-07-23 | デイビス、ボニー | Administration formulation for acetylcholinesterase inhibitors |
PT1140105E (en) * | 1998-12-24 | 2004-03-31 | Janssen Pharmaceutica Nv | GALANTAMINE COMPOSITION OF CONTROLLED LIBERTACAO |
CA2310950C (en) * | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | An efficacious dosage regiment of galantamine that reduces side effects |
CA2310990A1 (en) * | 2000-04-03 | 2000-10-09 | Michael Pontecorvo | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease |
-
2000
- 2000-06-27 CA CA002310926A patent/CA2310926C/en not_active Expired - Lifetime
-
2001
- 2001-03-28 EE EEP200200554A patent/EE200200554A/en unknown
- 2001-03-28 WO PCT/EP2001/003553 patent/WO2001074339A2/en not_active Application Discontinuation
- 2001-03-28 CN CN01807334A patent/CN1430514A/en active Pending
- 2001-03-28 AU AU2001265844A patent/AU2001265844B2/en not_active Ceased
- 2001-03-28 KR KR1020027011063A patent/KR20020086911A/en not_active Application Discontinuation
- 2001-03-28 CZ CZ20023543A patent/CZ20023543A3/en unknown
- 2001-03-28 MX MXPA02009777A patent/MXPA02009777A/en unknown
- 2001-03-28 HU HU0300566A patent/HUP0300566A3/en unknown
- 2001-03-28 SK SK1542-2002A patent/SK15422002A3/en unknown
- 2001-03-28 IL IL15206101A patent/IL152061A0/en unknown
- 2001-03-28 JP JP2001572084A patent/JP2003528913A/en not_active Withdrawn
- 2001-03-28 BR BR0109770-9A patent/BR0109770A/en not_active IP Right Cessation
- 2001-03-28 RU RU2002129298/14A patent/RU2002129298A/en not_active Application Discontinuation
- 2001-03-28 AU AU6584401A patent/AU6584401A/en active Pending
- 2001-03-28 EP EP01943200A patent/EP1272192A2/en not_active Withdrawn
- 2001-03-28 PL PL36127201A patent/PL361272A1/en not_active Application Discontinuation
-
2002
- 2002-09-12 BG BG107093A patent/BG107093A/en unknown
- 2002-09-26 HR HR20020778A patent/HRP20020778A2/en not_active Application Discontinuation
- 2002-10-02 NO NO20024746A patent/NO20024746L/en not_active Application Discontinuation
- 2002-10-02 ZA ZA200207935A patent/ZA200207935B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CZ20023543A3 (en) | 2003-03-12 |
WO2001074339A2 (en) | 2001-10-11 |
HUP0300566A2 (en) | 2003-06-28 |
HUP0300566A3 (en) | 2004-10-28 |
KR20020086911A (en) | 2002-11-20 |
HRP20020778A2 (en) | 2004-04-30 |
IL152061A0 (en) | 2003-05-29 |
NO20024746D0 (en) | 2002-10-02 |
BG107093A (en) | 2003-06-30 |
WO2001074339A3 (en) | 2002-09-12 |
BR0109770A (en) | 2003-02-04 |
JP2003528913A (en) | 2003-09-30 |
AU6584401A (en) | 2001-10-15 |
CA2310926A1 (en) | 2000-10-04 |
CN1430514A (en) | 2003-07-16 |
PL361272A1 (en) | 2004-10-04 |
CA2310926C (en) | 2002-10-15 |
NO20024746L (en) | 2002-11-28 |
AU2001265844B2 (en) | 2005-04-14 |
MXPA02009777A (en) | 2003-03-27 |
ZA200207935B (en) | 2004-01-30 |
EE200200554A (en) | 2004-04-15 |
SK15422002A3 (en) | 2003-04-01 |
EP1272192A2 (en) | 2003-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
ES2089027T3 (en) | TRANSMUCOSIC DOSAGE FORM. | |
RU2008116931A (en) | APPLICATION OF N-DESMETHYLCLOSAPINE FOR TREATMENT OF NEUROPSYCHIATRIC DISEASES IN PEOPLE | |
JP2005515966A5 (en) | ||
MXPA05012810A (en) | Memantine oral dosage forms. | |
JPS59193821A (en) | Use of fluoxetin as antianxiety | |
RU2002121546A (en) | SUBSTANCES FOR THE TREATMENT OF PSORIASIS | |
JP2004537500A5 (en) | ||
RU2002129298A (en) | APPLICATION OF GALANTAMINE FOR THE TREATMENT OF PSYCHONEUROLOGICAL BEHAVIOR ASSOCIATED WITH ALZHEIMER'S DISEASE | |
EP1372682A4 (en) | Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders | |
JP2002544233A5 (en) | ||
JP2002540148A5 (en) | ||
JP2003514025A5 (en) | ||
RU2003127718A (en) | APPLICATION OF FLUMAZENIL IN THE PRODUCTION OF A MEDICINE FOR TREATING COCAIN DEPENDENCE | |
AR023185A1 (en) | CANCER TREATMENT IMPROVED WITH TEMOZOLOMIDE | |
RU2003100081A (en) | METHODS AND COMPOSITIONS IN WHICH SULODEXIDE IS USED FOR THE TREATMENT OF DIABETIC NEPHROPATHY | |
JP2003523385A5 (en) | ||
CA2368352A1 (en) | Method for treating neurodegeneration | |
RU95112520A (en) | APPLICATION 4'-IODO-4'-DEOXIDOXORUBICINE FOR THE TREATMENT OF AMYLOIDOSIS, METHOD OF TREATMENT OF AMYLOIDOSIS | |
RU2006110550A (en) | USE OF OXCARBAZEPINE FOR TREATMENT OF DIABETIC NEUROPATHIC PAIN AND FOR IMPROVEMENT OF SLEEP | |
EA200300430A1 (en) | NEW PHARMACEUTICAL COMPOSITIONS CONTAINING EPINASTINES AND PSEVDOEDFEDRIN | |
CA2403674A1 (en) | The use of t3 for treating congestive heart failure | |
AR020167A1 (en) | METHOD FOR PREVENTION OF THE START OF ASTHMA | |
RU2001128509A (en) | METHOD FOR TREATING NEURODEGENERATION | |
KR890001558A (en) | Zephyron and its pharmaceutically acceptable acid addition salts alleviate panic disorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20060405 |